- Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
- Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
- Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
- Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
- Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
More ▼
Key statistics
On Tuesday, Arcturus Therapeutics Holdings Inc (ARCT:NMQ) closed at 21.48, 22.60% above the 52 week low of 17.52 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.84 |
---|---|
High | 24.24 |
Low | 20.52 |
Bid | 20.50 |
Offer | 24.58 |
Previous close | 21.48 |
Average volume | 911.56k |
---|---|
Shares outstanding | 26.93m |
Free float | 24.64m |
P/E (TTM) | -- |
Market cap | 578.50m USD |
EPS (TTM) | -4.02 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼